Step Two For Ilaris: Advisory Panel To Consider Whether To Add Gout Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
The biologic is the product of a Novartis strategy to test proof-of-concept early on; Phase III data look at time to first flare and pain intensity.